Roth Capital raised the firm’s price target on LB Pharmaceuticals (LBRX) to $37 from $31 and keeps a Buy rating on the shares post the Q1 report. The firm has included bipolar depression 1 in the stock’s valuation with a 30% potential approval. Roth sees “pipeline-in-a-molecule characteristics” for Amisulpride.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LBRX:
- LB Pharmaceuticals reports Q1 EPS (67c), consensus (67c)
- LB Pharmaceuticals initiated with a Buy at H.C. Wainwright
- LB-102 Bipolar Depression Trial Moves Forward: What LBRX Investors Should Know
- Craig-Hallum bullish on LB Pharmaceuticals, initiates with a Buy
- LB Pharmaceuticals initiated with a Buy at Craig-Hallum